ESR1 and breast carcinoma: Furthermore, from the EGF30008 and TAnDEM (TrAstuzumab in Dual HER2 ER-positive Metastatic breast cancer) trials, lapatinib + letrozole and trastuzumb + anastrozole were shown to improve time to progression versus AI monotherapy, respectively [52].